MBX Biosciences, Inc. (MBX) – What Are Researchers Thinking About This Stock?

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) have been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $87.00.

Several analysts have weighed in on MBX shares. Truist Financial boosted their target price on shares of MBX Biosciences from $70.00 to $88.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Barclays reaffirmed an “overweight” rating and issued a $88.00 price target on shares of MBX Biosciences in a report on Friday, August 7th. Guggenheim lifted their price objective on shares of MBX Biosciences from $88.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Wall Street Zen lowered shares of MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Mizuho upped their target price on MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th.

MBX Biosciences Price Performance

MBX Biosciences stock traded down $1.10 during midday trading on Monday, reaching $49.61. The company’s stock had a trading volume of 818,908 shares, compared to its average volume of 591,618. The stock has a market capitalization of $2.39 billion, a P/E ratio of -20.59 and a beta of 0.10. The stock’s 50-day simple moving average is $60.61 and its 200-day simple moving average is $49.22. MBX Biosciences has a 52-week low of $12.94 and a 52-week high of $72.64.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). As a group, equities research analysts expect that MBX Biosciences will post -3.10 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MBX Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Strs Ohio raised its position in MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company’s stock worth $48,000 after buying an additional 900 shares during the last quarter. State of Wyoming purchased a new stake in shares of MBX Biosciences in the 2nd quarter valued at $58,000. Quantbot Technologies LP acquired a new stake in shares of MBX Biosciences in the second quarter worth $213,000. Sei Investments Co. increased its stake in shares of MBX Biosciences by 17.4% in the first quarter. Sei Investments Co. now owns 8,989 shares of the company’s stock worth $268,000 after acquiring an additional 1,332 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of MBX Biosciences in the second quarter worth $287,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Endocrine Peptide platform to design engineered peptides intended to provide targeted activity, extended duration and more consistent treatment effects.

MBX’s lead program, MBX 1416, is an investigational long-acting parathyroid hormone receptor agonist being developed as a potential replacement therapy for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone.